Thermo Fisher Scientific Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $6.70B | $6.34B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | $2.94B |
| Depreciation & Amortization | — | — | — | — | — | — | — | $2.27B |
| Depreciation | $1.05B | $1.16B | $1.07B | $986.0M | $831.0M | $658.0M | $564.0M | $526.0M |
| Amortization | $1.73B | $1.95B | $2.34B | $2.40B | $1.76B | $1.67B | $1.71B | $1.74B |
| Stock-Based Compensation | $310.0M | $301.0M | $278.0M | $307.0M | $230.0M | $196.0M | $181.0M | $181.0M |
| Net Cash from Operating Activities | $7.82B | $8.67B | $8.41B | $9.15B | $9.31B | $8.29B | $4.97B | $4.54B |
| Investing Activities | ||||||||
| Capital Expenditures | $1.53B | $1.40B | $1.48B | $2.24B | $2.52B | $1.47B | $926.0M | $758.0M |
| Business Acquisitions | $4.04B | $3.13B | $3.66B | $39.0M | $19.40B | $38.0M | $1.84B | $536.0M |
| Net Cash from Investing Activities | $-4.05B | $-5.84B | $-5.14B | $-2.16B | $-21.93B | $-1.51B | $-1.49B | $-1.25B |
| Financing Activities | ||||||||
| Dividends Paid | $636.0M | $583.0M | $523.0M | $455.0M | $395.0M | $337.0M | $297.0M | $266.0M |
| Stock Repurchases | $3.00B | $4.00B | $3.00B | $3.00B | $2.00B | $1.50B | $1.50B | $500.0M |
| Net Cash from Financing Activities | $1.80B | $-6.79B | $-3.62B | $-2.81B | $6.58B | $959.0M | $-3.12B | $-2.24B |
| Net Change in Cash | $5.84B | $-4.06B | $-440.0M | $4.05B | $-5.85B | $7.91B | $305.0M | $756.0M |
| Free Cash Flow | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B |